Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
The global market for Neulasta (Pegfilgrastim) and Biosimilar was estimated to be worth US$ 2431 million in 2023 an...
Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.
The global market for Lucentis (Ranibizumab) and Biosimilar was estimated to be worth US$ 1124 million in 2023 and is forecast to a readjusted size of US$ 843.4 mill...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
The global market for Herceptin (Trastuzumab) and Biosimilar was estimated to be worth US$ 4512 million in 2023 and is forecast to a readjusted size of US$ 6303.7 million by 2030 with a CAGR of 4.8% during the forecast period 2024-2030
North American market for...
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
The global market for Enbrel (Etanercept) and Biosimilar was estimated to be worth US$ 6350 million in 2023 and is forecast...
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
The global market for Enbrel (Etanercept) Biosimilar was estimated to be worth US$ 1247 million in 2023 and is forecast to a...
Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
The global market for Bevac...
Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
The global market for Avast...
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
The global market for Adalimumab (Humira) and Biosimilar was estimated to be worth US$ 22420 million in 2023 and is forecast to a readjusted size of US$ 15520 million by 2030 with a CAGR of -5.1% during the forecast period 2024-2030
The expiration of patents for ad...
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
The global market for Adalimumab Monoclonal Antibody Biosimilar was estimated to be worth US$ 421 million in 2023 and is forecast to a readjusted size of US$ 958.9 million by 2030 with a CAGR of 12.5% during the forecast period 2024-2030
The introduction of Humira...
Humira is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
The global market for Humira Biosimilar was estimated to be worth US$ 421 million in 2023 and is forecast to a readjusted size of US$ 958.9 million by 2030 with a CAGR of 12.5% during the forecast period 2024-2030
The introduction of Humira biosimilars is expected to i...
Our team would be happy to assist you with your queries.
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals